(Q37881408)

English

Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review

scientific article published on 27 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

0 references

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

author name string

Linda J M Oostendorp

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Peep F M Stalmeier

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

A Rogier T Donders

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Winette T A van der Graaf

4

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Petronella B Ottevanger

5

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

27 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1053-1061

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in 1,038 women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of metastatic breast cancer: looking towards the future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Considerations in treatment choice for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment options for breast cancer resistant to anthracycline and taxane

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting of adverse drug reactions in randomised controlled trials - a systematic survey

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting of Safety Results in Published Reports of Randomized Controlled Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Better reporting of harms in randomized trials: an extension of the CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship of quantitative estrogen-receptor level and clinical response to cytotoxic chemotherapy in advanced breast cancer. An extramural analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel therapeutic approaches to the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy in older women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970045-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70045-6

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37881408&oldid=2166286772"